Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech company announced some progress on lead asset, POLB 001.
Skillington, fresh from the JPMorgan conference in San Francisco, announces "very positive" in vivo data for POLB 001, showing efficacy in reducing cancer immunity-induced cytokine release syndrome (CRS). This development bolsters the company's hypothesis and strengthens their patent applications in this area.
Skillington highlighted POLB 001's dual role as both a preventative and a treatment for CRS, a notable advancement since no approved preventative therapies currently exist for this condition. This development could significantly benefit patients and ease healthcare system burdens. With its potential as an oral therapy, POLB 001 stands out in a market dominated by injectable treatments, offering the convenience of at-home administration.
Further enhancing Poolbeg's strategic position, the addition of David Allmond as Chief Business Officer and the formation of a scientific advisory board have provided valuable insights for program positioning and market needs.
Finally, Skillington discusses the immense market potential for POLB 001, estimating it at $1 billion, particularly in treating multiple myeloma, high-grade lymphoma, and acute lymphoblastic leukemia.
